Curated News
By: NewsRamp Editorial Staff
August 19, 2025
Branded Legacy Partners with McMaster to Combat Addiction Crisis
TLDR
- Branded Legacy gains a strategic advantage by partnering with McMaster University to accelerate product evaluations and regulatory approvals in the addiction treatment market.
- The collaboration combines McMaster's clinical trial expertise with Bio-Legacy's scientific experience to develop rigorous evaluation protocols for addiction interventions.
- This partnership aims to reduce overdose deaths and promote long-term recovery through accessible, cost-effective addiction treatment solutions.
- Branded Legacy's intranasal delivery technology enables precise dosing for opioid overdose reversal and potential vaccine applications.
Impact - Why it Matters
This partnership addresses the critical global addiction crisis that has claimed countless lives through overdoses and substance abuse. With opioid-related deaths reaching epidemic proportions in many countries, innovative solutions like Branded Legacy's intranasal delivery system could revolutionize emergency response and treatment accessibility. The collaboration with a prestigious research institution like McMaster University lends scientific credibility and accelerates the development of evidence-based interventions. For communities devastated by addiction, this represents hope for more effective, accessible treatments that could save lives and support long-term recovery, potentially reducing healthcare costs and social burdens associated with substance abuse disorders.
Summary
Branded Legacy (OTC: BLEG), a diversified holdings company specializing in health and wellness solutions, has announced a groundbreaking partnership between its subsidiary Bio-Legacy Evaluative Group and McMaster University. This collaboration aims to evaluate innovative products for populations affected by addictions, combining McMaster's renowned expertise in addiction medicine, clinical trials, and guideline development with Bio-Legacy's real-world scientific experience. The partnership will advance rigorous evaluations, clinical trials, and regulatory submissions to develop accessible, cost-effective interventions focused on reducing overdose deaths, minimizing drug-related harms, and promoting long-term recovery.
The company's innovative approach includes a patented intranasal naloxone delivery device that enhances accessibility and dosing precision for opioid overdose treatment, representing a significant advancement in emergency response capabilities. This platform also enables nasal delivery of vaccines and other medications, opening opportunities in global markets for rapid pandemic response and improved access in underserved regions. The InvestorWire platform, part of the Dynamic Brand Portfolio at IBN, played a crucial role in disseminating this important news through its advanced wire-grade press release syndication and extensive network of distribution channels, ensuring maximum reach to investors and the broader public.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Branded Legacy Partners with McMaster to Combat Addiction Crisis
